[Diagnosis, treatment and gene mutation analysis in children with holocarboxylase synthetas deficiency]
Tong Wang1, Jun Ye, Lian-Shu Han
1Department of Pediatric Endocrinology and Genetic Metabolism, Shanghai Institute for Pediatric Research, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Insights
Holocarboxylase synthetase (HCS) deficiency in children causes lethargy, acidosis, and skin issues. Early biotin treatment is effective, resolving symptoms and normalizing metabolites.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Context:
- Holocarboxylase synthetase (HCS) deficiency is a rare metabolic disorder.
- Early diagnosis and treatment are crucial for managing HCS deficiency.
Purpose:
- To detail the clinical presentation, diagnostic methods, and treatment outcomes for children with HCS deficiency.
- To identify the spectrum of HCS gene mutations in affected children.
Summary:
- Eleven children with HCS deficiency presented with neurological and dermatological symptoms, alongside metabolic acidosis.
- Diagnosis involved mass spectrometry and biotinidase activity assays, with HCS gene sequencing revealing mutations R508W and V363D as prevalent in Chinese children.
- Ten patients responded well to biotin therapy, showing symptom resolution within weeks and normalization of metabolic markers within months.
Impact:
- This study highlights the diagnostic utility of biochemical and genetic analyses for HCS deficiency.
- It confirms the efficacy of early biotin intervention, improving clinical outcomes in affected children.
- Identified common HCS gene mutations provide insights into the genetic landscape of the disorder in specific populations.
Objective:
To report the clinical diagnosis, treatment and follow-up of children with holocarboxylase synthetas(HCS) deficiency and explore the gene mutation spectrum of the disease.
Methods:
Eleven children with HCS deficiency were enrolled. Mass spectrometry analysis and biotinidase activity determination were used for diagnosis of HCS deficiency. HCS gene mutations were analyzed by PCR directed sequencing methods. Ten patients received oral biotin treatment (10-40 mg/d). Clinical effects of biotin treatment were observed.
Results:
All 11 cases developed apathetic, lethargy and metabolic acidosis at different degrees, and 10 cases presented with skin lesions. The average blood 3-hydroxyisovaleryl-carnitine concentrations and urinary 3-methylcrontonylglycine and methylcitrate concentrations increased significantly. The biotinidase activity increased, being higher over 30% of the normal reference value. Four mutations in HCS gene were identified, and they were c.1522C>T (R508W), c.1088T>A (V363D), c.126G>T (E42D) and c.1994G>C (R665P) (a new variant) and the frequency was 50%, 29%, 7% and 14% respectively. The symptoms disappeared in 10 cases 1-2 weeks after biotin treatment, and blood and urinary abnormal metabolites were gradually reduced to normal 2-6 months after treatment.
Conclusions:
HCS deficiency is characterized by nervous system damage, skin lesions and metabolic acidosis. Mass spectrometry analysis, biotinidase activity determination and gene mutation analysis may be helpful in the definite diagnosis of this disorder. The effect of early biotin treatment is satisfactory. The mutations R508W and V363D might be hot-spots in Chinese children with HCS deficiency.
Related Concept Videos
Inborn Errors of Metabolism
Pedigree Analysis
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Lysosomal Hydrolases
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...


